학술논문
Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer
Document Type
Article
Author
Source
In Gynecologic Oncology November 2020 159(2):483-490
Subject
Language
ISSN
0090-8258